All News
Maintenance regimen for #AAV- AZP and On demand RTX inferior to RTX q6 months. Scheduled RTX for 18 or 36 months is better and results the same. AES similar in all group #ACR23 @RheumNow #YearinReview https://t.co/SpA9mY6syZ
TheDaoIndex KDAO2011 ( View Tweet)
Slides (vexingly) unavailable for ILD guideline talk, thanks @DrPujaMehta1 for the quick snap!
As expected, ILD guidelines "suggestion" for who to screen is "way way more than before"
My thoughts in full:
https://t.co/QC7ZLxjdJk
@RheumNow #ACR23 https://t.co/BuhJFgpfZh
Mike Putman EBRheum ( View Tweet)
Obviously.
@RheumNow #ACR23 https://t.co/yw6lk0Zai7
Mike Putman EBRheum ( View Tweet)
What are you using for ANCA vasculitis maintenance?
Not much difference in AZA vs. RTX on demand
70% relapse free in RTX q6 month for 18 months
NO difference in similar 36 month group
Should maintenance w/ RTX only last for 18 months?
Food for thought
@RheumNow #ACRbest https://t.co/zNdIEODpeS
Robert B Chao, MD ( View Tweet)
NEJM: Clinical Examination of the Cervical Spine (full read, with video). Great overview of Cx exam, useful in evaluation of axial neck pain, radiculopathy, or myelopathy; info on dermatomes, reflexes, Lhermites sign, etc https://t.co/QYD1ZahqTS https://t.co/K0XhlHYXoz
Dr. John Cush RheumNow ( View Tweet)
Novel approach to ank spond. Case report. #YearinReview #ACR23 @RheumNow https://t.co/fWb1qdEcOS
TheDaoIndex KDAO2011 ( View Tweet)
Very cool targeted T cell ab treatment against TRBV9+ T cells provided remission in ankylosing spondylitis!
Albeit only case report
However Phase 2 ongoing
@RheumNow #ACR23 https://t.co/pm64QeTo1U
Robert B Chao, MD ( View Tweet)
Brilliant summary slide re:RA and PsA during an as-always entertaiing by Dr. Seo
Personal opinion?
-Persolimab will have narrow role & may cause CA
-BIME will be 2nd line for PsA
-Tyk-2's will be the next big thing
Also... time for H2H trials!!!
@RheumNow #ACR23 https://t.co/lDvsK8h7WH
Mike Putman EBRheum ( View Tweet)
#ACR23 YiR! Dr. P. Seo reviews 2023 novel therapeutic agents we may see on the horizon. @RheumNow https://t.co/d0V41jAh3G
Dr. Rachel Tate ( View Tweet)
Considering a career in Rheumatology?
Dr. Philip Seo shares latest data from Lancet Rheumatology on the burden of disease of MSK disorders
👉123%⬆️since 1990
👉⬆️by 50% in 2050!
Year in Review
#ACR23 @RheumNow @rheumarhyme @doktora_ging @PhRheumaJr https://t.co/iypUn9MTu6
sheila ( View Tweet)
Can colchine reduce need for knee/hip replacement? Dr Seo #YearReview #ACR23 @RheumNow https://t.co/EpMl2nDZQ6
TheDaoIndex KDAO2011 ( View Tweet)
NORD-STAR study
RA pts treated with MTX + certolizumab, abatacept, tocilizumab or triple therapy
Certolizumab and Abatacept share 1st place!
Toci 2nd
Should we place abatacept higher on the RA tx hierarchy?
@RheumNow #ACR23 https://t.co/QvyzkLOcmX
Robert B Chao, MD ( View Tweet)
Still disgesting NORD-STAR, kind of surprised by the TCZ response?
As per usual, ABA is probably an under-used option for RA
@RheumNow #ACR23 https://t.co/QKyeuhqnXB
Mike Putman EBRheum ( View Tweet)
Novel therapeutics for #inflammatoryArthritis #YearInReciew #ACR23 @RheumNow https://t.co/9flVkGRn8v
TheDaoIndex KDAO2011 ( View Tweet)
Novel therapeutics for #SLE and #SSc #ACR23 @RheumNow https://t.co/yBSaTpNZLN
TheDaoIndex KDAO2011 ( View Tweet)
#ACR23 I’ll be at the Poster Hall tomorrow 12/11/23 between 9-11 am to present our work on clinical and biomarkers to exclude imminent autoimmune connective tissue disease #lupus #sjogren in people with ANA+. Do come and say hi 👋🏼 😃 https://t.co/wzRB7QXZsF
Md Yuzaiful Md Yusof ( View Tweet)
Takeaways from #ACR23 #ReviewCourse session on Systemic Sclerosis Screening for Organ Involvement - Dr. Francesco Boin
1. Always approach SSc as a systemic disease (see slide). Survival is determined by subset (limited vs diffuse) and organ manifestations.
2. Autoantibodies… https://t.co/TmrPqLJYzD https://t.co/ajHDVpUbhO
Paul Sufka, MD psufka ( View Tweet)
Axial PsA or AS? #ACR23 Abs #0492 finds age > 45 at LBP onset, female sex, higher frequency of PsO, and shorter time to dx may be better predictors of axial PsA. https://t.co/3sEj8NxtzP @rheumnow https://t.co/nV7NHk7WtD
Dr. Rachel Tate ( View Tweet)
Deucravacitinib tx found to have comparable effects on PsA disease activity and PROs after 16 weeks in both male and female patients. #ACR23 Abs 0485 https://t.co/w36rX3B77K @rheumnow https://t.co/q41ioJDMML
Dr. Rachel Tate ( View Tweet)
Racial/ethnic minority PsA pts less likely to be diagnosed w/in 12 mos from symptom onset (50% vs 71%; P < 0.001) and more frequently uninsured (8% vs. 1%; P < 0.001) compared to white pts. #ACR23 Abs #0490 https://t.co/MKO9hblGYT @rheumnow https://t.co/K8GgkhHOqw
Dr. Rachel Tate ( View Tweet)